Pharmaceutical Sciences, 2009, Vol.15, No.1, Page 103- 108 ﺩﺍﺭﻭﺋﻲ، ﻋﻠﻮﻡ١٣٨٨ ﺩﻭﺭﻩ١٥ ﺷﻤ، ﺎﺭﻩ١ ، ١٠٨ ‐ ١٠٣ ﻣﻜﻤﻞ اﺛﺮات ﻳﺎري ﺧﻮراﻛ ﻲ ﻣﻨﻴﺰﻳﻢ در ﻣﻴﮕﺮﻧﻲ ﺣﻤﻼت از ﭘﻴﺸﮕﻴﺮي ﻣﻬﺪو رﺿﺎ ي 1 ، ﻋﻠ ﻲ ﻃﺮ ﻳ اﺳﻔﻨﺠﺎﻧ ﻘﺖ ﻲ* 2 ، ﻣﻬﺮاﻧﮕ ﻴ اﺑﺮاﻫ ﺰ ﻴ ﻤ ﻲ ﻣﻤﻘﺎﻧ ﻲ 2 ، ﻃﺎﻟﺒ ﻣﻬﻨﺎز ﻲ 3 ، ﺳ ﻴ ﻣﻘﺎﻣ ﻗﺎﺋﻢ ﺟﻤﺎل ﺪ ﻲ 2 1 ﺗﺤﻘ ﻣﺮﻛﺰ ﻴ ﻛﺎرﺑﺮد ﻘﺎت ي داروﺋ ﻲ ﭘﺰﺷﻜ ﻋﻠﻮم داﻧﺸﮕﺎه ﻲ ﺗﺒﺮ ﻳ ﺰ، اﻳﺮان ﺗﺒﺮﻳﺰ،. 2 داﻧﺸﻜﺪه ي ﺗﻐﺬ و ﺑﻬﺪاﺷﺖ ﻳ ﻪ، داﻧﺸﮕ ﺗﺒﺮﻳﺰ، ﭘﺰﺷﻜﻲ ﻋﻠﻮم ﺎه اﻳﺮان ﺗﺒﺮﻳﺰ،. 3 ﻣﺮﻛﺰ اﻋﺼﺎب ﻋﻠﻮم ﺗﺤﻘﻴﻘﺎت، ﺗﺒﺮﻳﺰ، ﭘﺰﺷﻜﻲ ﻋﻠﻮم داﻧﺸﮕﺎه ﺗﺒﺮﻳﺰ اﻳﺮان. درﻳﺎﻓﺖ ﺗﺎرﻳﺦ: 5 / 8 / 87 ﭘﺬﻳﺮش ﺗﺎرﻳﺦ، : 28 / 10 / 87 Effects of Oral Magnesium for Migraine Prophylaxis Mahdavi R. 1 , Tarighat Esfanjani A.* 2 , Ebrahimi M. 2 , Talebi M. 3 , Ghaemmagami J. 2 1 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 2 School of Health and Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran. 3 Neuroscience Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Received: 26 Oct. 2008, Accepted: 17 Jan. 2009 Objectives: Conflicting results have been reported for positive effects of magnesium supplementation on migraine prophylaxis. The objective of this study was to assess whether, magnesium oxide in addition to routine treatments in adults, reduces migrainous headache frequency, migraine days and headache severity. Methods: In this 2-month clinical trial, effects of 500 mg/day oral magnesium oxide for migraine prophylaxis and serum magnesium concentration in 77 migrainous adults (case=33, control=44) aged 34.10±9.61 years, were assessed. Weight and height were measured and body mass index was calculated. Results: Significant reduction in migraines, migraine days, headache severity and migraine index in the both groups compared with baseline, were observed. In magnesium oxide group compared with control group, 50% or greater reduction in migraines (P<0.01) and headache severity (P<0.05) were significant. Statistically non-significant decreases in migraine index and migraine days in the magnesium oxide group were reported. Magnesium supplementation increased significantly (P<0.001) serum magnesium concentration while in control group no difference was seen. Conclusion: In spite of oral magnesium oxide supplementation (500 mg/day) in addition to routine treatments appears to be effective in migraine prophylaxis, larger trials involving this safe, appealing complementary therapy are needed. Keywords: migraine, magnesium supplementation, prophylaxis. زﻣ ﻴ و ﻨﻪ ﻫ ﺪف: ﻧﺘﺎ ﻳ ﻧﻘ و ﺿﺪ ﺞ ﻴ ﻀ ﻲ ﻣﺜﺒﺖ اﺛﺮات ﻣﻮرد در ﺗﺮﻛ ﻴ ﻣﻨ ﻣﺨﺘﻠﻒ ﺒﺎت ﻴ ﺰ ﻳ ﺧﻮراﻛ ﻢ ﻲ ﭘ در ﻴ ﺸﮕ ﻴ ﺮ ي ﺳﺮدردﻫﺎ از ي ﻣ ﻴ ﮕﺮﻧ ﻲ ﺷﺪه ﮔﺰارش اﺳﺖ. ﻟﺬا ا ﻳ ﻦ ﻣﻄﺎﻟﻌﻪ ﻫﺪف ﺑﺎ ﺑﺮرﺳ ﻲ ﺗﺄﺛ ﻴ ﺮ اﻛﺴ ﻴ ﺪ ﻣﻨ ﻴ ﺰ ﻳ ﻢ ﭘ در ﻴ ﺸﮕ ﻴ ﺮ ي ﻣ ﺣﻤﻼت از ﻴ ﮕﺮﻧ ﻲ ﺑﺰرﮔﺴﺎﻻن اﻧﺠﺎم ﻳ ﺎﻓﺖ. روش ﻫﺎ: ﻃ ﻲ ﻳ ﻛﺎرآزﻣﺎﺋ ﻚ ﻲ ﺑﺎﻟ ﻴ ﻨ ﻲ ﺗﺼﺎدﻓ ﻲ، ﺑﺮ ﻋﻼوه روﺗ درﻣﺎن ﻴ اﻛﺴ ﻦ، ﻴ ﻣﻨ ﺪ ﻴ ﺰ ﻳ ﺧﻮراﻛ ﻢ ﻲ ﺑﺎ دوزmg/day 500 ﺑﻪ ﻣﺎه دو ﻣﺪت ﺑﻪ77 ﺑ ﻴ ﻣ ﺑﻪ ﻣﺒﺘﻼ ﺑﺰرﮔﺴﺎل ﻤﺎر ﻴ ﮕﺮن) 33 و ﻣﺪاﺧﻠﻪ ﮔﺮوه در ﻧﻔﺮ44 ﮔﺮوه در ﻧﻔﺮ ﺷﺎﻫﺪ( ﻣ ﺑﺎ ﻴ ﺎﻧﮕ ﻴ ﺳﻨ ﻦ ﻲ61 / 9 ± 10 / 34 ﺗﺠﻮ ﺳﺎل، ﻳ ﺗﺄﺛ و ﺷﺪ ﺰ ﻴ ﻧﻤﺎ و ﺷﺪت ﻣﺪت، ﺗﻜﺮر، ﺑﺮ آن ﺮ ﻳ ﻪ ي ﻣ ﻴ ﻧ و ﮕﺮن ﻴ ﻣﻨ ﺳﻄﺢ ﺑﺮ ﺰ ﻴ ﺰ ﻳ ارز ﻣﻮرد ﺳﺮم ﺗﺎم ﻢ ﻳ ﺎﺑ ﻲ ﻗﺮار ﮔﺮﻓﺖ. ﺑ وزن و ﻗﺪ ﻴ ﻤﺎران اﻧﺪازه ﮔ ﻴ ﺮ ي ﻧﻤﺎ و ﻳ ﻪ ي ﺗﻮده ي ﺑﺪﻧ ﻲ ﻣﺤﺎﺳﺒﻪ ﺷﺪ. ﻳ ﺎﻓﺘﻪ ﻫﺎ: ﻛﻪ داد ﻧﺸﺎن ﻣﻄﺎﻟﻌﻪ ﻧﺘﺎﺋﺞ ﻣﻌﻨ ﻛﺎﻫﺶ وﺟﻮد ﺑﺎ ﻲ ﺗﻜﺮر دار و ﺷﺪت ﻣﺪت،، ﻧﻤﺎ ﻳ ﻪ ي ﻣ ﻴ ﮕﺮن، ﮔﺮوه دو ﻫﺮ در ﻣﺪاﺧﻠﻪ ﺷﺎﻫﺪ و ﺑﻪ ﻧﺴﺒﺖ ﻣﺪاﺧﻠﻪ از ﻗﺒﻞ، ﻛﺎﻫﺶ ﺣﺪاﻗﻞ50 % ﺣﻤﻼ ﻣ ت ﻴ ﮕﺮﻧ ﻲ ﮔﺮوه در ﻣﺪاﺧﻠﻪ ﺑﻪ ﻧﺴﺒﺖ ﮔﺮوه ﺷﺎﻫﺪ ازً ﺻﺮﻓﺎ ﻧﻈﺮ ﺗﻌﺪاد) 01 / 0 P< ( ﺷﺪت و) 05 / 0 P< ( ﺣﻤﻼت ﻣﺎﺑ ﻴ ﮔﺮوه دو ﻦ ﻣﻌﻨ ﻲ دار ﺑﻮد و ﺗﻔﺎوت روزﻫﺎ ي ﺳﺮدرد ﻧﻤﺎ و ﻳ ﻪ ي ﻣ ﻴ ﮕﺮن، آﻣﺎر ﻟﺤﺎظ از ي ﻣﻌﻨ ﻲ ﻧ دار ﺒﻮد. ﻣ ﻴ ﻣﻨ ﺰان ﻴ ﺰ ﻳ ﺳﺮم ﺗﺎم ﻢ ﻧ ﻴ ﺰ، در ﮔﺮوه ﻣﺪاﺧﻠﻪ ﺷﺎﻫﺪ ﮔﺮوه ﺑﻪ ﻧﺴﺒﺖ اﻓﺰا ﻳ ﺶ ﻣﻌﻨ ﻲ دار ي) 001 / 0 P< ( ﻳ ﺎﻓﺖ. ﻧﺘ ﻴ ﺠﻪ ﮔ ﻴ ﺮ ي: ﻋﻠ ﻴ ﻧﺘﺎ ﺮﻏﻢ ﻳ ا ﻣﺜﺒﺖ ﺞ ﻳ ﻣﻄﺎﻟﻌﻪ، ﻦ ﺑﺮا ي اﺳﺘﻔﺎده ي روﺗ ﻴ از ﻦ ﻣﻜﻤﻞ اﻛﺴ ﻴ ﺪ ﻣﻨ ﻴ ﺰ ﻳ ﻢ درﻣﺎن ﺑﺎ ﻫﻤﺮاه داروﺋ ﻲ در ﭘ ﻴ ﺸﮕ ﻴ ﺮ ي ﻛﻨﺘﺮل و ﻣ ﺣﻤﻼت ﻴ ﮕﺮن ﺑﺰرﮔﺴﺎﻻن ﺑ ﻣﻄﺎﻟﻌﺎت، ﻴ ﺸﺘﺮ ي ﺿﺮور ي ﻣ ﻧﻈﺮ ﺑﻪ ﻲ رﺳﺪ. واژه ﻫﺎ ي ﻛﻠ ﻴ ﺪ ي: ﻣ ﻴ ﮕﺮن، ﻣﻜﻤﻞ ﻳ ﺎر ي ﻣﻨ ﻴ ﺰ ﻳ ﭘ ﻢ، ﻴ ﺸﮕ ﻴ ﺮ ي. * ﻣﺴﺌﻮل ﻧﻮﻳﺴﻨﺪه: اﺳﻔﻨﺠﺎﻧﻲ، ﻃﺮﻳﻘﺖ ﻋﻠﻲ داﻧﺸﺠﻮيPh.D ﺗﻐﺬﻳﻪ، ﻋﻠﻮم داﻧﺸﻜﺪه اﻳﺮان، ﺗﺒﺮﻳﺰ، ﺗﺒﺮﻳﺰ، ﭘﺰﺷﻜﻲ ﻋﻠﻮم داﻧﺸﮕﺎه ﺗﻐﺬﻳﻪ و ﺑﻬﺪاﺷﺖ ي ﺗﻠﻔﻦ: 3 - 3357581 - 0411 ، ﻧﻤﺎﺑﺮ: 3357584 - 0411 *Corresponding Author: Ali Tarighat Esfanjani, PhD Student, School of Health and Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran. Tel: +98-411-3357581-3; Fax:+98-411- 3357584; E-mail: tarighata@yahoo.com